Icosavax is based out of Seattle. Icosavax is a biopharmaceutical company leveraging its VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax���s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. The firm last filed a Form D notice of exempt offering of securities on 2021-04-07. The notice included securities offered of Equity
Contact Info
Contact information is taken directly from publicly disclosed SEC filings.
Icosavax, Inc.1930 BOREN AVE., SUITE 1000
SEATTLE WA 98101
Business Phone: (206) 737-0085
SEC SIC CODE:
2836-BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
2836-BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)